AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
PDF (3.5 MB)
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Basic Medicine | Publishing Language: Chinese | Open Access

Paeoniflorin alleviates LPS-induced aerobic glycolysis in HK-2 cells by modulating the PI3K/AKT/HIF-1α pathway

Jing XIE1Ruonan LI1Huihui GAO1Shunkai YANG1Yuqing MA2( )
First School of Clinical Medicine, Lanzhou University, Lanzhou, Gansu
Department of Anesthesiology, the First Hospital of Lanzhou University, Lanzhou, Gansu, China
Show Author Information

Abstract

Objective

To investigate the effects of paeoniflorin (PF) on lipopolysaccharide (LPS) - induced aerobic glycolysis in renal tubular epithelial cell line HK-2 and its underlying mechanism of action.

Methods

This study consists of a preliminary experiment and a formal experiment. Preliminary experiment: CCK-8 assay and RT-qPCR were used respectively to measure cell viability and mRNA expression levels of inflammatory factors in HK-2 cells after LPS stimulation to determine the optimal LPS concentration for modeling as well as to evaluate the toxicity of PF and screen for its appropriate concentration. Formal experiment: HK-2 cells were divided into control group (CON group), LPS group, LPS+PF group and LPS+PF+ 740Y-P group. LPS was used to establish a cell model of sepsis associated-acute kidney injury (SA-AKI) in HK-2 cells, and then the cell model was treated with PF and PI3K activator 740Y-P, correspondingly for 24 h. CCK-8 assay was employed to detect cell viability, and Extracellular Acidification Rate (ECAR) Kit was utilized to measure the rate. The contents of IL-1β, IL-18, lactic acid (Lac) and lactate dehydrogenase A (LDHA) were determined with ELISA. Western blotting was applied to detect the expression of p-PI3K, p-AKT, HIF-1α, pyruvate kinase 2 (PKM2, a key enzyme in aerobic glycolysis) and NOD-like receptor thermal protein domain associated protein 3 (NLRP3), and immunofluorescence assay was performed to observe the expression and distribution of PKM2.

Results

① Our preliminary experiment identified that the optimal concentration of LPS for modeling was 20. 0 μg/mL, a safe dosage range of PF was 0~100. 0 μmol/L, and its optimal therapeutic concentration was 25. 0 μmol/L. ② Compared with the CON group, LPS stimulation resulted in significantly decreased cell viability (P<0. 05), increased ECAR (P<0. 05), elevated contents of IL-1β, IL-18, Lac and LDHA (P<0. 05), up-regulated protein levels of p-PI3K, p-AKT, HIF-1α, p-PKM2 and NLRP3 (P< 0. 05), and enhanced fluorescence intensity of PKM2 in the nucleus of cells (P<0. 05). Compared with the model group, PF treatment reversed all above effects induced by LPS stimulation (all P<0. 05). Compared with the LPS+PF group, in the LPS+PF+740Y-P group, ECAR was elevated (P<0. 05), the contents of IL-1β, IL-18, Lac and LDHA were increased (P<0. 05), and the relative expression levels of p-PI3K, p-AKT, HIF-1α, p-PKM2 and NLRP3 were increased (P<0. 05), and the fluorescence intensity of PKM2 was strengthened (P<0. 05) and enhanced in the nucleus (P<0. 05).

Conclusion

PF reduces aerobic glycolysis in HK-2 cells and alleviates the inflammatory response by inhibiting the PI3K/AKT/HIF-1α signaling pathway.

CLC number: R285.5; R329.26; R692.6 Document code: A

References

【1】
【1】
 
 
Journal of Army Medical University
Pages 2483-2494

{{item.num}}

Comments on this article

Go to comment

< Back to all reports

Review Status: {{reviewData.commendedNum}} Commended , {{reviewData.revisionRequiredNum}} Revision Required , {{reviewData.notCommendedNum}} Not Commended Under Peer Review

Review Comment

Close
Close
Cite this article:
XIE J, LI R, GAO H, et al. Paeoniflorin alleviates LPS-induced aerobic glycolysis in HK-2 cells by modulating the PI3K/AKT/HIF-1α pathway. Journal of Army Medical University, 2025, 47(20): 2483-2494. https://doi.org/10.16016/j.2097-0927.202505035

135

Views

1

Downloads

0

Crossref

0

Scopus

0

CSCD

Received: 15 May 2025
Revised: 24 September 2025
Published: 30 October 2025
© 2025 Journal of Army Medical University

This is an open access article under the CC BY license (https://creativecommons.org/licenses/by/4.0/).